Penumbra Inc (PEN) stock

Penumbra Inc grew revenue 17.0% to $1.56B over the twelve months to Sep 30, 2026. Operating income rose 9.5% to $189.25M, moving the operating margin from 13.0% to 12.1%. Free cash flow was $200.29M, up 31.2% from a year earlier. At the latest close the market valued the company at $12.68B, 81.0 times its earnings.

Index membership is inferred from the holdings of funds that track each index (IJH, SPMD, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Penumbra develops and manufactures medical devices designed to address challenging vascular conditions throughout the body, operating as a single segment focused on thrombectomy, embolization, and access solutions. The company's thrombectomy portfolio includes computer-assisted vacuum aspiration systems, continuous aspiration mechanical catheters, and reperfusion devices used to treat ischemic stroke, pulmonary embolism, deep vein thrombosis, and acute limb ischemia. In addition, it produces peripheral and neurovascular embolization devices, such as detachable coils and occlusion systems, alongside guide and intermediate access catheters and neurosurgical evacuation tools. Penumbra primarily sells these products directly to healthcare providers and hospital systems for use by specialist physicians, including interventional radiologists, neuroradiologists, vascular surgeons, neurosurgeons, and interventional cardiologists.